Abstract Type 1 diabetes is caused by destruction of insulinproducing beta cells of the pancreas.
Introduction
Type 1 diabetes is a multifactorial disease caused by a complex interaction of genetic and environmental factors [1] . The etiology of type 1 diabetes is immune-mediated, through mostly organ-specific autoimmunity against insulin-producing beta cells of the pancreas [1] . Immunomodulation is therefore expected to accelerate or inhibit type 1 diabetes. In fact, acceleration of type 1 diabetes by interferon therapy and protection against type 1 diabetes by immune suppression have been reported [2, 3] . Recent progress in anti-cancer therapy by immune-checkpoint blockade, such as anti-PD-1 and anti-CTLA4 monoclonal antibodies, has markedly improved the prognosis of patients with advanced cancers [4] . These drugs activate anti-tumor immunity by blocking inhibitory signals of T lymphocytes [5] . Activation of immunological pathways, however, is expected to accelerate immunemediated diseases. In fact, the development of autoimmune thyroid diseases and type 1 diabetes, including fulminant type 1 diabetes, has been reported [6] . Fulminant diabetes is a subtype of type 1 diabetes, characterized by very rapid disease progression [7, 8] . The development of fulminant type 1 diabetes is a major concern, because death is likely to occur unless proper treatment is initiated immediately after diagnosis due to very rapid disease progression [8] . In this review, the development of type 1 diabetes with immune-checkpoint therapy and its etiological background is discussed.
Development of immune-mediated disease in patients treated with anti-PD-1 antibody antibody, nivolumab. The first cases were the development of autoimmune thyroid diseases in two patients with advanced melanoma treated with nivolumab [9] . The third case was the development of type 1 diabetes in a patient treated with anti-PD-1 antibody. A male patient in his 70s had been treated with nivolumab without any adverse effect for 9 months until he developed general fatigue, thirst and polyuria 2 or 3 days before attending our hospital for treatment with nivolumab. Laboratory tests on the day of the visit showed marked hyperglycemia [plasma glucose (PG) 593 mg/dl] and ketosis [3 hydroxybutyrate 730 lmol/ l (normal range \85)]. He was admitted, and insulin treatment was started. Insulin secretary capacity assessed by glucagon stimulation test after recovery from ketosis showed that his endogenous insulin secretion was completely abolished (\0.02 ng/ml before and after glucagon stimulation). Pancreatic enzyme levels (amylase, lipase and elastase) were all increased, and islet-related autoantibodies (GAD, IA-2 and ZnT8 Abs) were all negative. From these data, other than the higher level of HbA1c (9.2 %) than the diagnostic criterion (\8.7 %), fulminant type 1 diabetes was suspected [10] . It was fortunate for him that his regular visit to the hospital for nivolumab treatment was scheduled only 2 days after he noticed the symptoms of thirst and polyuria. In view of the abrupt onset and very rapid progression of the disease, as evidenced by the complete loss of endogenous insulin soon after its onset, if his visit had been scheduled later, he might have suffered diabetic ketoacidosis and coma, leading to a life-threatening situation.
The development of type 1 diabetes has been reported in 13 patients, including 5 suspected cases of fulminant type 1 diabetes, treated with nivolumab in Japan from 4 July 2014 to 15 May 2016 (Table 1) . Although not all cases with type 1 diabetes are reported and the full details of each patient are not available, the estimated frequency of type 1 diabetes is as high as 0.20 % based on the estimated number of patients treated with nivolumab (n = 6346) (data from website: https://www.opdivo.jp/) in 22 months, corresponding to an incidence of 110/100,000 persons/year, which is much higher than reported incidences of type 1 diabetes in Japan (1.4-2.2/100,000 persons/year) [11] . Of note is the very high percentage, as high as 40 % (5/13), of fulminant type 1 diabetes in nivolumab-associated type 1 diabetes. The abrupt onset and rapid progression of fulminant type 1 diabetes in patients treated by oncologists who are not familiar with fulminant type 1 diabetes are major concerns, because a life-threatening situation due to ketoacidosis and coma may occur, leading to death in the worst cases. The Japan Diabetes Society and the Japanese 
Development of fulminant type 1 diabetes in different ethnic groups
Type 1 diabetes associated with immune-checkpoint therapy has been reported not only in Japan, but also in other countries [6, [14] [15] [16] [17] (Table 2 ). In particular, fulminant type 1 diabetes has been reported in a Caucasian subject treated with an anti-PD-1 antibody, pembrolizmab [6] . Marked differences in the frequencies of fulminant type 1 diabetes are well recognized [8] . Fulminant type 1 diabetes is relatively common in Japan and East Asian countries, while it is very rare in Caucasian subjects [8] . The development of fulminant type 1 diabetes in Caucasian subjects, who are otherwise resistant to fulminant type 1 diabetes, treated with anti-PD-1 antibody suggests the importance of the PD-1 pathway in the etiology of fulminant type 1 diabetes.
PD-1 (programmed cell death 1): a negative regulator of the immune reaction
Fine tuning of the immune reaction is essential for protection of the body from infection, malignant tumors and immune-mediated diseases. Immune reaction to foreign antigens such as viruses as well as altered self-antigens such as tumors is both positively and negatively regulated. The main pathway is the presentation of antigen peptide in the context of class II molecules of the major histocompatibility complex (MHC) by antigen-presenting cells (APC), such as dendritic cells, and recognition of these antigen-MHC complexes by the T cell antigen receptor (TCR) on the surface of T lymphocytes (signal 1) (Fig. 1) . In addition to signal 1, recognition of ligands, termed B7, on APC by a receptor, termed CD28, on T cells is necessary to initiate the immune reaction (signal 2) (Fig. 1) . These positive signals are negatively regulated by several molecules, so as to limit too much activation, prevent damage of normal tissues and eventually stop the immune reaction. One of these is CTLA4, a receptor expressed on T cells, which recognizes the same B7 molecules as ligands, as in the case of CD28. Thus, the same B7 molecules transmit a positive signal when recognized by a CD28 receptor, while a negative signal is transmitted when recognized by a CTLA4 receptor, providing fine tuning of the immune reaction, as with the axels and brakes of a car. Another negative regulator is programmed cell death 1 (PD-1), which is a receptor expressed on antigen-stimulated T cells and other immune cells [5] . PD-1 has two ligands, PD-L1 and PD-L2. Upon binding with these ligands, PD-1 negatively regulates the immune reaction by inhibiting the TCR signaling pathway (signal 1), which inactivates ZAP70, a major integrator of TCR-mediated signaling [5] (Fig. 1) . These inhibitory pathways function as immune system checkpoints, negatively regulating T cell activation and thereby limiting and stopping excessive immune reactions.
Inhibition of PD-1 pathway for treatment of cancer and malignant tumors
Since inhibition of negative regulators is expected to increase the immune reaction to pathogen and tumor antigens, antibodies directed against PD-1 and CTLA-4 have been developed for the treatment of cancer and malignant tumors [4] . Another reason for the development of anti-PD-1 antibodies for anti-tumor therapy is that one of the ligands of PD-1, PD-L1, is expressed not only on immune cells, but also on many cell types, including tumor cells, and tumor cells appear to escape immune attack through their expression of PD-L1. Among these anti-PD-1 b Fig. 1 Axels and brakes in the immune reaction. Immune reaction against a certain antigen is regulated both positively (axels) and negatively (
brakes). a Axels (positive regulation). A main pathway is the stimulation of T cells by antigen presented in the context of major histocompatibility complex (MHC) class II molecules by antigenpresenting cells (APC) and recognition of antigen-MHC class II complexes by the T cell antigen receptor (TCR) on T cells (signal 1).
In addition to signal 1, a costimulatory signal induced by the interaction of the CD28 receptor on T cells with its ligands, B7 [B7.1 (CD80) and B7.2 (CD86)] (signal 2), is necessary to start the immune reaction against antigen. b Brakes (negative regulation). CTLA4, a receptor expressed on T cells, recognizes as ligands the same B7 molecules as those recognized by CD28 and inhibits the immune reaction at both the level of ligand recognition by competing with the same ligands as those of CD28 and the level of signal transduction in the CD28-mediated costimulatory pathway. PD-1 is another receptor expressed on T cells acting as a negative regulator of the immune reaction. Upon recognition of its ligands, PDL1 (also known as B7-H1 or CD274) and PDL2 (B7-DC or CD273), PD-1 negatively regulates the immune reaction by inhibiting the TCR signaling pathway (signal 1) through inactivation of ZAP70, a major integrator of TCR-mediated signaling. PD-1 also inhibits the CD28-mediated costimulatory pathway (signal 2) by inhibiting PI3 kinase (PI3 K). 
PD-1 pathway and type 1 diabetes
Since PD-1 is a negative regulator of the immune reaction, abnormality in the PD-1 pathway was expected to cause hyperactivity of immune function, leading to the development of autoimmune diseases, such as type 1 diabetes. In fact, inhibition of the PD-1 pathway in the NOD mouse, an animal model of type 1 diabetes, was reported to accelerate type 1 diabetes [24] . Mice deficient in PD-1 were reported to develop autoimmunity against diverse target organs depending on their genetic background [25] [26] [27] [28] . The development of type 1 diabetes was observed only when the mouse genetic background was NOD [29] , suggesting that genetic susceptibility to type 1 diabetes is necessary for the development of type 1 diabetes in PD-1 deficiency. Since PD-1 negatively regulates the immune reaction at the level of signal 1, which is generated when T cells recognize the antigen-MHC complex through TCR (Fig. 1) , the effect of PD-1 is expected to be antigen-specific. This is probably the reason why only a limited target organ is affected by autoimmune attack in PD-1 deficiency. In humans, we previously reported the genetic association of PDCD1, the gene encoding PD-1, with type 1 diabetes [30] . More recently, low expression of PD-1 in T cells was reported in autoimmune type 1 diabetes, and the expression level was associated with PDCD1 polymorphism [31] . Thus, inhibition of the PD-1 pathway by anti-PD-1 antibodies, as in the case of immune checkpoint therapy for cancer, is expected to induce type 1 diabetes. In fact, the development of type 1 diabetes has been reported as mentioned above [6, [14] [15] [16] [17] , and other autoimmune diseases, such as autoimmune thyroid diseases, myasthenia gravis and interstitial pneumonia, have also been reported in patients treated with anti-PD-1 monoclonal antibodies [9, 32, 33] .
Thus, in both animal models and humans, inhibition of the PD-1 pathway induces autoimmune diseases including type 1 diabetes, indicating the contribution of the PD-1 pathway to the development of type 1 diabetes and other autoimmune diseases. The development of fulminant type 1 diabetes surprised us, because fulminant type 1 diabetes is classified as idiopathic type 1 diabetes because of the lack of islet-related autoantibodies in most cases [7, 8] and absence of insulitis in biopsy specimens of patients [7] . Although it is still under extensive discussion whether or not fulminant type 1 diabetes is of autoimmune etiology, the consensus is that immune-mediated mechanisms are involved [8, 34, 35] . The development of both autoimmune type 1 diabetes and fulminant type 1 diabetes in patients treated with anti-PD-1 antibodies suggests the contribution of the PD-1 pathway in autoimmune as well as fulminant type 1 diabetes and that fulminant type 1 diabetes shares, at least in part, molecular mechanisms with autoimmune type 1 diabetes.
PD-1 and CTLA4 in type 1 diabetes and other autoimmune diseases
In contrast to the development of type 1 diabetes in a substantial number of patients treated with anti-PD-1 antibodies, type 1 diabetes has not been reported in patients treated with anti-CTLA4 antibodies alone, in either Japan or the USA (http://www.yervoy.com/). In contrast, autoimmune thyroid diseases have been reported with both anti-PD-1 and anti-CTLA4 antibody treatment. One possible explanation is the smaller number of patients treated with the anti-CTLA4 antibody ipilimumab in Japan (n = 245 in 6 months, data from website: https://file. bmshealthcare.jp/yervoy/pdf/side_effect0229_2.pdf) than those treated with the anti-PD-1 antibody nivolumab (n = 6346 in 22 months); therefore, a lower frequency of side effects, as in the case of type 1 diabetes, has not been observed. Another possibility, however, is the difference in the contribution of the PD-1 and CTLA4 pathways to the etiology of type 1 diabetes. CTLA4 is a well-known susceptibility gene for autoimmune thyroid diseases [36] . The association of CTLA4 with type 1 diabetes was also reported [37] , but subsequent studies revealed that this association was mainly due to autoimmune thyroid diseases concomitant with type 1 diabetes [38, 39] , and when type 1 diabetes was stratified by the presence or absence of autoimmune thyroid diseases, an association with CTLA4 was observed in type 1 diabetes concomitant with AITD, but not in type 1 diabetes without AITD [38] . These data, together with the development of AITD but not type 1 diabetes with anti-CTLA4 antibody therapy, suggest that CTLA4 may not be a primary factor in the development of type 1 diabetes. Further studies with a larger number of subjects treated with anti-CTLA4 antibodies are necessary to verify this hypothesis.
Even if CTLA4 is not a primary factor in the development of type 1 diabetes, inhibition of CTLA4 accelerates the immune reaction in general; therefore, ongoing immune reaction against beta cells is expected to be accelerated. Combination therapy of anti-CTLA4 with anti-PD-1 antibodies may therefore further increase the risk of type 1 diabetes as compared with anti-PD-1 antibodies alone by accelerating the immune reaction that has already been initiated and targeted to beta cells of the pancreas. Careful observation and appropriate management are needed in patients treated with combination therapy with anti-CTLA4 and anti-PD-1 antibodies.
Future directions
Since the original diseases in which immune checkpoint inhibitors are used, advanced cancer and malignant tumors, are life-threatening conditions, these drugs are indispensable for treatment of these patients. Although type 1 diabetes, including fulminant type 1 diabetes, is also a life-threatening condition, insulin treatment can save patients and normal daily life can be continued with insulin treatment if there is early diagnosis and optimal treatment from the onset. It is therefore important for all doctors and medical staff using this class of drugs to be aware of the possibility of the development of type 1 diabetes in general, and fulminant type 1 diabetes in particular, in patients treated with immune checkpoint inhibitors. As mentioned in the warning and recommendations from the Committee on Type 1 Diabetes of the Japan Diabetes Society, symptoms and laboratory parameters should be monitored in all patients treated with immune checkpoint inhibitors, and as soon as type 1 diabetes is suspected, consultation with a diabetologist is recommended for the diagnosis and treatment of type 1 diabetes. The number of patients treated with anti-PD-1 antibodies is markedly increasing because of their efficacy and expanding application to a wide variety of malignant tumors, including treatment with combination therapy of anti-PD-1 antibodies and anti-CTLA4 antibodies. Careful monitoring and appropriate management of immune-mediated side effects, including type 1 diabetes, are therefore strongly recommended.
In addition to saving patients from life-threatening conditions due to type 1 diabetes, extensive study on the clinical and genetic background of the patients who develop type 1 diabetes with immune checkpoint inhibitors will clarify the genetic basis and molecular pathogenesis of the disease. In particular, studies on fulminant type 1 diabetes induced by immune checkpoint inhibitors are expected to clarify the molecular mechanisms of fulminant type 1 diabetes, whose etiology is still largely unknown, leading to the development of effective methods for prevention, intervention and cure of the disease. A multicenter study on fulminant type 1 diabetes induced by immunecheckpoint inhibitors by the Committee on Type 1 Diabetes of the Japan Diabetes Society is now in progress.
